Welcome to our dedicated page for Castle Biosciences SEC filings (Ticker: CSTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Castle Biosciences, Inc. (CSTL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq-listed issuer. Castle Biosciences files reports with the U.S. Securities and Exchange Commission that cover its financial performance, governance changes, risk factors and material events related to its molecular diagnostics business in dermatologic and gastroenterological disease.
Investors can review current reports on Form 8-K, where Castle discloses items such as quarterly financial results, updated revenue guidance, the release of investor presentations and amendments to its bylaws. For example, 8-K filings describe when the company announces earnings for periods such as the quarter ended September 30, 2025, or when its board adopts amended and restated bylaws addressing stockholder meetings, director nominations, voting standards and indemnification provisions.
Alongside 8-Ks, users can access annual reports on Form 10-K and quarterly reports on Form 10-Q (when available in the SEC feed). These filings typically contain audited or reviewed financial statements, management’s discussion and analysis of results, details on Castle’s test portfolio, information about markets served and disclosures about risks associated with its diagnostics operations.
For those monitoring governance and capital structure, the SEC filings also identify Castle Biosciences’ state of incorporation (Delaware), the class of securities registered (common stock, $0.001 par value per share) and its listing on The Nasdaq Global Market under the symbol CSTL.
Stock Titan enhances this raw filing data with AI-powered summaries that explain key points in accessible language. Users can quickly see the main themes of a lengthy 10-K or 10-Q, identify notable changes in guidance or governance reported in 8-Ks, and navigate directly to sections that matter most for understanding Castle Biosciences’ molecular diagnostics business.
CASTLE BIOSCIENCES INC President & CEO Derek J. Maetzold reported an exercise-and-sell transaction in company stock. On April 6, 2026, he exercised stock options to acquire 6,214 shares of common stock at an exercise price of $2.39 per share, converting previously granted options into shares.
On the same date, Maetzold sold 6,214 directly held shares of common stock at a weighted-average price of about $25.03 per share, along with additional open-market sales through several family and estate-planning trusts totaling 9,836 shares sold overall. According to the filing, these sales were made under a Rule 10b5-1 trading plan adopted on December 3, 2025, indicating they were pre-scheduled rather than opportunistic trades.
After these transactions, Maetzold continues to hold 21,479 shares directly and maintains substantial indirect ownership through multiple trusts, including 48,852 shares in The Maetzold Descendants 2020 Trust and 85,959 shares in DJM Grantor Retained Annuity Trust No. 5, among other vehicles.
Castle Biosciences is asking stockholders to vote at its 2026 annual meeting on electing three Class I directors, ratifying KPMG as auditor, approving executive pay on an advisory basis and approving its non-employee director compensation policy.
Management highlights 2025 revenue of approximately $344 million, above guidance, driven by strong demand for DecisionDx-Melanoma and TissueCypher, whose test volumes rose 37% over 2024. The company reports about $300 million in cash, cash equivalents and marketable securities, an eight‑member largely independent, classified board, and governance features such as stock ownership guidelines, a clawback policy, prohibitions on hedging and pledging, and fully independent key committees.
Castle Biosciences (CSTL) President and CEO Derek J. Maetzold reported exercising stock options and selling shares in a pre-planned transaction. He exercised options for 550 shares of common stock at $2.39 per share, then sold a total of 4,172 common shares at a weighted-average price of $25.551 per share under a Rule 10b5-1 trading plan.
After these transactions, Maetzold holds 21,479 common shares directly and 13,732 options, with additional indirect holdings through several family trusts, including 50,209 shares in The Maetzold Descendants 2020 Trust and 42,673 shares in the Derek Maetzold 2020 Irrevocable Trust.
Castle Biosciences director Rodney Cotton exercised restricted stock units to receive common shares. On March 26, 2026, he exercised 5,329 Restricted Stock Units (RSUs), each representing one share of common stock, at an exercise price of $0.00 per share.
Following the transaction, his direct holdings of Castle Biosciences common stock increased to 19,331 shares. The RSUs relate to a prior grant of 15,988 RSUs awarded on March 26, 2024, which vest in three equal annual installments beginning March 26, 2025. This filing reflects a routine compensation-related equity vesting and exercise event, not an open‑market purchase or sale.
Derek Maetzold reported proposed sales of Common shares of CSTL under Rule 144, listing multiple transactions dated between 01/05/2026 and 03/18/2026.
The filing lists numerous individual dispositions by Mr. Maetzold and related trusts, with transaction entries showing share counts and dollar values for each trade, including a 23,179-share entry on 03/12/2026. The filing is a disclosure of proposed/resale transactions under Rule 144.
Castle Biosciences Inc ownership update: The Vanguard Group filed an amendment reporting it beneficially owns 0 shares (0%) of Castle Biosciences common stock as disclosed in this Schedule 13G/A.
The filing explains an internal realignment of Vanguard subsidiaries that resulted in disaggregated reporting under SEC Release No. 34-39538. The filing is signed by Ashley Grim, Head of Global Fund Administration.
Castle Biosciences CEO Derek J. Maetzold reported open-market sales of 19,300 shares of Common Stock of CASTLE BIOSCIENCES INC. He sold 18,650 shares at a weighted-average price of $25.93 on March 17, 2026 and 650 shares at $25.39 on March 18, 2026, leaving 21,479 shares held directly.
The filing notes these transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 3, 2025. Maetzold also reports indirect ownership of additional Common Stock through multiple family and grantor retained annuity trusts, including 51,566 shares held by The Maetzold Descendants 2020 Trust and other trusts where he serves as trustee or beneficiary.
Castle Biosciences Inc. President and CEO Derek J. Maetzold reported open-market sales of a total of 30,779 shares of common stock on March 13 and 16, 2026, at weighted-average prices of $25.447, $25.964 and $26.680 per share. These transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 3, 2025. Following the sales, he holds 40,779 shares directly and also has indirect holdings through several family and grantor retained annuity trusts.
CASTLE BIOSCIENCES INC Chief Commercial Officer Juvenal Tobin reported an open-market sale of 20,863 shares of common stock. The shares were sold at a weighted-average price of $25.24 per share, with individual trade prices ranging from $24.90 to $25.70. After this transaction, Tobin directly holds 86,825 shares. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025, indicating the timing was set in advance rather than decided opportunistically.